Table 3 Replication result of positive SNPs associated with disease progression in advanced prostate cancer patients treated with ADT.

From: Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer

Gene SNP Genotype

Patients, n (%)

Events, n (%)

Median, mo

HR (95% CI) a

P a

ATG16L1 rs78835907

 GG

187 (37.3)

176 (38.8)

19

1.00

 

 GA

238 (47.5)

206 (45.4)

23

0.74 (0.60–0.91)

0.005

 AA

76 (15.2)

72 (15.9)

16

0.95 (0.70–1.28)

0.721

 GA/AA vs GG

   

0.78 (0.64–0.95)

0.014

 AA vs GG/GA

   

1.14 (0.86–1.49)

0.365

 Trend

   

0.91 (0.78–1.05)

0.193

  1. Abbreviations: ADT, androgen deprivation therapy; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.
  2. aAdjusted by age, clinical stage, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir and treatment modality. P < 0.05 are in boldface.
Back to article page